Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M . (2010). Metformin blocks the stimulative effect of a high energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid acid synthase. Endocr Relat Cancer 17: 351–360.

Algire C, Zakikhani M, Blouin M-J, Shuai JH, Pollak M . (2008). Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr Relat Cancer 15: 833–839.

Blake DA, McLean NV . (1989). A colorimetric assay for the measurement of -glucose consumption by cultured cells. Anal Biochem 177: 156–160.

Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, Meier CR . (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304–1308.

Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745–6752.

Currie CJ, Poole CD, Gale EA . (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766–1777.

DeFronzo RA, Goodman AM . (1995). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541–549.

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N . (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804–10812.

Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y . (2008). Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 233: 203–210.

Engelman, Cantley . (2010). Chemoprevention meets glucose control. Can Prev Res 3: 1049–1052.

El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X . (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223–228.

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD . (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304–1305.

Fantin VR, St Pierre J, Leder P . (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425–434.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G et al. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2267–2270.

Hardie DG . (2006). Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 131: 973.

Hardie DG . (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774–785.

Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T et al. (2007). Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Can Prev Res 3: 1077–1083.

Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL et al. (2008). Important role of the LKB1-AMPK pathway in suppressing tumourigenesis in PTEN deficient mice. Biochem J 412: 211–221.

Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807–810.

Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283–293.

Kalaany NY, Sabatini DM . (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725–731.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390–401.

Kroemer G, Pouyssegur J . (2008). Tumor cell metabolism: cancer's Achilles’ heel. Cancer Cell 13: 472–482.

Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ . (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322–326.

Larsson SC, Mantzoros CS, Wolk A . (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121: 856–862.

Larsson SC, Orsini N, Wolk A . (2005). Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679–1687.

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM . (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620–1625.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al. (2009). Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031–2040.

Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA . (2010). Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Can Prev Res 3: 1066–1076.

Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y et al. (2010). Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70: 741–751.

Owen MR, Doran E, Halestrap AP . (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 (Part 3): 607–614.

Pollak M . (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915–928.

Pollak M . (2009). Do cancer cells care if their host is hungry? Cell Metab 9: 401–403.

Pollak M . (2010). Metformin and other biguanides in oncology: advancing the research agenda. Can Prev Res 3: 1060–1065.

Russell III RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. (2004). AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495–503.

Sakamoto K, McCarthy A, Smith D, Green KA, Grahame HD, Ashworth A et al. (2005). Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24: 1810–1820.

Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659–3662.

Shackelford DB, Shaw RJ . (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563–575.

Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, Depinho RA et al. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329–3335.

Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642–1646.

Tennant DA, Duran RV, Gottlieb E . (2010). Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267–277.

Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H et al. (2008). Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99: 2136–2141.

van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME . (2010). High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 105: 1258–1264.

Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al. (2007). Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793–1800.

Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R . (2009). Diabetes and cancer. Endocr Relat Cancer 16: 1103–1123.

Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T et al. (2009). Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4: e5137.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M . (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269–10273.

Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN . (2008). The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila, PA) 1: 369–375.